Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is MEway Pharma's primary focus?
- MEway Pharma develops solutions that combine nebulization and inhalation technologies to improve pulmonary drug delivery.
- What is the status of MEway Pharma?
- MEway Pharma is currently inactive, having ceased operations in September 2022.
- When was MEway Pharma founded and where is its headquarters located?
- MEway Pharma was founded in January 2014 and is headquartered in Ra'anana, Israel.
- What is MEway Pharma's flagship product?
- MEway Pharma's flagship product is the UltraFlow Nebulizer, a handheld device designed for fine particle emission, rapid flow rate, and breath-actuated mechanisms to improve drug delivery efficacy and shorten treatment time.
- What was MEway Pharma's total funding raised and from which investor?
- MEway Pharma raised a total of $1,000,000 in a Seed round in January 2015, with Sanara Ventures as an investor. For full financing history, users can refer to startupim.
- How many employees did MEway Pharma have?
- MEway Pharma had 3 employees.
- Who are the founders of MEway Pharma?
- The founders of MEway Pharma are Eran Eilat, Joshua Altman, and Moshe Tshuva.
- What is the product stage of MEway Pharma's offerings?
- MEway Pharma's products are in the clinical trial stage.
- Does MEway Pharma hold any patents?
- Yes, MEway Pharma holds 1 patent.